Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Effects of cessation of imatinib mesylate therapy in patients with IM-refractory gastrointestinal stromal tumors (GIST)as visualized by FDG-PET scanning

Effects of cessation of imatinib mesylate therapy in patients with IM-refractory gastrointestinal stromal tumors (GIST)as visualized by FDG-PET scanning. American Society of Clinical Oncology (ASCO) Conference; New Orleans, LA. 2004.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.